Clark G., Anti-Cancer Compounds . . . Acta Crystallographica C45 Part 1 (1989) pp. 67-71. |
Kirshenbaum M., (R,R)-2,2.sup.1 -[1,2-Ethanediylbis[Imino(1-Methyl-2,1-Ethanediyl)]]-Bis[5-Nitro-1H-Benz [DE] Isoquinoline-1,3-(2H)-Dione] Dimethanesulfonate (DMP 840) Cancer Res 54 (1994) pp. 2199-2206. |
Goodgame et al., "Metal Complexes of Ligands Containing Intercalating Units," Chemical Abstracts, 115(4) :801, Jul. 1991. |
PCT Search Report, Jul. 24, 1995. |
Arthaud et al., "Preclinical toxicity of the anticancer agent DMP 840 in mice, rats and dogs," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2290, 1993. |
Bousquet et al., "Bis-naphthalimides demonstrate significant antitumor activity in vivo," Proc. Amer. Assoc. Cancer Res., 34:374. Abstract 2230, 1993. |
Bra na et al., "Bis-naphthalimides, a novel class of antitumor agents," Proc. Amer. Assoc. Cancer Res., 34:383. Abstract 2285, 1993. |
Chen et al., "Effects of a bis-naphthalimide anti-cancer agent XB596 on cell cycle kinetics of MCF-7 human breast tumor cells," Proc. Amer. Assoc. Cancer Res., 34:348. Abstract 2074, 1993. |
Chen et al., "XB596, a promising bis-naphthalimide anti-cancer agent," Anti-Cancer Drugs, 4:447-457, 1993. |
Cornbleet et al., "Mitoxantrone for the Treatment of Advanced Breast Cancer: Single-agent Therapy in Previously Untreated Patients," Eur. J. Cancer Clin. Oncol., 20:1141-1146, 1984. |
Czerniak et al., "Magnitude and duration of anti-tumor response caused by DMP 840, a novel bis-naphthalimide anti-tumor agent, against human solid tumor xenografts in vivo," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2289, 1993. |
Hsiang et al., "Topoisomerase II-Mediated DNA Cleavage by Amonafide and Its Structural Analogs," Molec. Pharmcol., 36:371-376, 1989. |
McRipley et al., "Evaluation of DMP 840, a novel anti-tumor agent, in murine and human tumor models in vivo," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2291, 1993. |
Papp et al., "Mechanistic and anti-proliferative activities of DMP 840, a novel bis-naphthalimide anti-tumor agent," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2288, 1993. |
Qian et al., "Bis-naphthalimides bind strongly to DNA and inhibit topoisomerase II but do not stabilize topoisomerase II/DNA cleavable complexes," Proc. Amer. Assoc. Cancer, 34:426. Abstract 2542, 1993. |
Stafford et al., "DNA binding characteristics of DMP 840, a novel bis-naphthalimide anti-tumor agent," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2292, 1993. |
Sun et al., "Synthesis and anti-proliferative properties of novel bis-naphthalimides, CMP 840 and its stereoisomers," Proc. Amer. Assoc. Cancer Res., 34:384. Abstract 2287, 1993. |
Talbot et al., "Anthrapyrazole CI941: A Highly Active New Agent in the Treatment of Advanced Breast Cancer," J. Clin. Oncol., 9:2141-2147, 1991. |
Berners-Price, "Stereospecific Hydrogen-Bonding in Mononucleotide Adducts of Platinum Anticancer Complexes in Aqueous Solution," J. Am. Chem. Soc., 115:8649-8659, 1993. |
Bowler and Lippard, "Modulation of platinum antitumor drug binding to DNA by linked and free intercalators," Biochemistry, 25:3031-3038, 1986. |
Denny and Baguley, "Acridine-based anticancer drugs," Molecular Aspects of Anticancer Drug-DNA Interactions, vol. 2, chapter 7 (Neidle and Waring, eds.), CRC Press, Boca Raton, FL, 1994. |
Farrell, N., "Nonclassical Platinum Antitumor Agents: Perspectives for Design and Development of New Drugs Complementary to Cisplatin," Cancer Invest., 11(5) :578-589, 1993. |
Gean et al., "Preparation, characterization and the anticancer activity of a novel series of triaminemonochloroplatinum(II) cations linked to anthraquinone intercalators," Eur. J. Med. Chem., 26:593-598, 1991. |
Kraker et al., "Anticancer Activity in Murine and Human Tumor Cell Lines of Bis(platinum) Complexes Incorporating Straight-Chain Aliphatic Diamine Linker Groups," J. Med. Chem., 35:4526-4532, 1992. |
Gibson et al., "Preparation, Characterization and Anticancer Activity of a Series of cis-PtCl.sub.2 Complexes Linked to Anthraquinone Intercalators," J. Med. Chem., 34:414-420, 1991. |
McKeage and Kelland, "New Platinum Drugs," Molecular Aspects of Anticancer Drug-DNA Interactions, vol. 1, chapter 6 (Neidle and Waring, eds.), CRC Press, Boca Raton, Fl, 1993. |
Lee et al., "DNA-Directed Alkylating Agents. 5. Acridinecarboxamide Derivatives of (1,2-Diaminoethane) dichloroplatinum(II)," J. Med. Chem., 35:2983-2987, 1992. |
Palmer et al., "Synthesis, DNA binding interactions and biological activity of bis-platinum(II) complexes of N,N,N', N'-tetrakis(2-aminoethyl)diamines," Anti-Cancer Drug Design, 7:385-401, 1992. |
Roberts et al., "Interaction of novel bis(platinum) complexes with DNA," Nucl. Acids Res., 17(23) :9719-9733, 1989. |
Sundquist et al., "Synthesis, Characterization and Biological Activity of cis-Diammineplatinum(II) Complexes of the DNA Intercalators 9-Aminoacridine and Chloroquine," J. Am. Chem. Soc., 112:1590-1596, 1990. |
Webster et al., "cis-Bis(pyridine)platinum(II) Organoamides with Unexpected Growth Inhibition Properties and Antitumor Activity," J. Med. Chem., 35:3349-3353, 1992. |
Woynarowski et al., "Effects on isolated and intracellular DNA of AB018, a novel cytotoxic drug with DNA alkylating, groove binding, and intercalating moieties," Fifth International Congress on Anti-cancer Chemotherapy, Paris, France, Jan. 31-Feb. 3, 1995. |
Woynarowski et al., "Effects on isolated and intracellular DNA of AB018, a novel cytotoxic drug with DNA alkylating, groove binding, and intercalating moieties,"Abstract for poster presentation for Fifth International Congress on Anti-cancer Chemotherapy, Paris, France, Jan. 31-Feb. 3, 1995. |
Yamashita et al., "Cytotoxicity of Platinum(IV) and Platinum(II) Complexes Containing 1R,2R-Cyclohexanediamine as a Ligand," Biol. Pharm. Bull., 16(10) :1014-1018, 1993. |